DIM (Diindolylmethane) vs NMN (Nicotinamide Mononucleotide)

Mechanism

DIM is formed from indole-3-carbinol (I3C, from cruciferous vegetables) via acid condensation in the stomach. It modulates estrogen metabolism by promoting the 2-hydroxylation pathway (producing 2-hydroxyestrone, considered 'protective' estrogen) over the 16alpha-hydroxylation pathway (producing 16alpha-hydroxyestrone, considered proliferative) and the 4-hydroxylation pathway (producing 4-hydroxyestrone, genotoxic). DIM binds the aryl hydrocarbon receptor (AhR), inducing Phase I (CYP1A1, CYP1A2) and Phase II enzymes that facilitate estrogen detoxification. It also inhibits aromatase and has anti-androgen receptor effects (competitive binding).

Standard Dosing

100-200mg DIM daily

Timing

With meals (fat enhances absorption). Consistent daily dosing for estrogen metabolism modulation.

Cycle Duration

ongoing or cycle 8-12 weeks on, 4 weeks off

Side Effects

• Harmless dark-colored urine
• GI upset
• Headache
• Changes in menstrual cycle
• Potential anti-androgenic effects at high doses in men

Contraindications

• Estrogen-dependent conditions where estrogen reduction is not desired
• Concurrent tamoxifen/AI therapy (without oncologist approval)
• Pregnancy/lactation

Best Stacking Partners

Mechanism

NMN is a direct biosynthetic precursor to NAD+ via the salvage pathway enzyme nicotinamide phosphoribosyltransferase (NAMPT). Elevated NAD+ activates sirtuins (SIRT1-7), PARP DNA repair enzymes, and CD38/CD157 signaling. SIRT1 activation deacetylates PGC-1alpha (mitochondrial biogenesis), FOXO transcription factors (stress resistance), and NF-kB (anti-inflammatory). NMN also enters cells via the Slc12a8 transporter, recently identified in the gut.

Standard Dosing

500-1000mg daily

Timing

Morning on empty stomach. Sublingual absorption bypasses first-pass metabolism.

Cycle Duration

ongoing

Side Effects

• Mild GI discomfort
• Flushing (rare, unlike niacin)
• Mild headache during initial use

Contraindications

• Active cancer (theoretical concern: NAD+ may fuel rapidly dividing cells)
• Pregnancy/lactation (insufficient data)
• Theoretical concern in active cancer (NAD+ fuels all rapidly dividing cells)

Best Stacking Partners